Efficacy and safety of intravenous ketamine treatment in Japanese patients with treatment‐resistant depression: A double‐blind, randomized, placebo‐controlled trial

Yohei Ohtani; Hideaki Tani; Kie Nomoto‐Takahashi; Taisuke Yatomi; Kengo Yonezawa; Sota Tomiyama; Nobuhiro Nagai; Keisuke Kusudo; Shiori Honda; Sotaro Moriyama; Shinichiro Nakajima; Takashige Yamada; Hiroshi Morisaki; Yu Iwabuchi; Masahiro Jinzaki; Kimio Yoshimura; Tsuyoshi Eiro; Sakiko Tsugawa; Sadamitsu Ichijo; Yu Fujimoto; Tomoyuki Miyazaki; Takuya Takahashi; Hiroyuki Uchida

doi:10.1111/pcn.13734

Abstract

Although the antidepressant effect of ketamine on treatment-resistant depression (TRD) has been frequently reported in North American and European countries, evidence is scarce among the Asian population. We aimed to evaluate the efficacy and safety of intravenous ketamine in Japanese patients with TRD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ohtani et al. (2024) studied this question.

synapsesocial.com/papers/68e5a2c4b6db64358753d414 https://doi.org/10.1111/pcn.13734

View Full Paper

Ask AI

Bookmark

Share

Efficacy and safety of intravenous ketamine treatment in Japanese patients with treatment‐resistant depression: A double‐blind, randomized, placebo‐controlled trial

Abstract

Discussion

Cite This Study

Efficacy and safety of intravenous ketamine treatment in Japanese patients with treatment‐resistant depression: A double‐blind, randomized, placebo‐controlled trial

Abstract

Discussion

Cite This Study

Keep reading

Keep reading